PAMELA CHADWELL: Open Payments
NPI 1861434623 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$430 in 15 payments from 10 companies in 2025. Trend: 2023 $316 · 2024 $1,125 · 2025 $430
Food & beverage: $430
| Company | Payments | Amount |
|---|---|---|
| ACADIA Pharmaceuticals Inc | 1 | $110 |
| Neurocrine BioSciences, Inc. | 2 | $84 |
| Viatris Specialty LLC | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| PFIZER INC. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| JAZZ PHARMACEUTICALS INC. | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
Products named: NUPLAZID, INGREZZA, YUPELRI, REXULTI, XIFAXAN, NURTEC ODT, ZENPEP, AUSTEDO XR.
Industry payments across OK — which companies pay providers there.
